Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1153-1156

  Kanbayashi, Yuko ^a   Hosokawa, Toyoshi ^a,b   Kitawaki, Jo ^b   Taguchi, Tetsuya ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Nab paclitaxel; Opioids; Paclitaxel; Peripheral neuropathy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CAPECITABINE; CARBOPLATIN; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; GABAPENTIN; GOSHA JINKI GAN; MORPHINE; NEDAPLATIN; NEUROTROPIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PACLITAXEL; PREGABALIN; SHAKUYAKU KANZO TO; STEROID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DIABETES MELLITUS; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AGED; ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES;

EID: 84875888129     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mielke S, Sparreboom A and Mross K: Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer 42: 24-30, 2006.
2. Wolf S, Barton D, Kottschade L, Grothey A and Loprinzi C: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44: 1507-1515, 2008.
3. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M and Kiernan MC: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15: 3081-3094, 2008.
4. Carlson K and Ocean AJ: Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach. Clin Breast Cancer 11: 73-81, 2011.
5. Strasser F, Demmer R, Bohme C, Schmitz SF, Thuerlimann B, Cerny T and Gillessen S: Prevention of docetaxel- or paclitaxelassociated taste alterations in cancer patients with oral glutamine: A randomized, placebo-controlled, double-blind study. Oncologist 13: 337-346, 2008.
6. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, Takagi T and Taniwaki M: Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs 21: 877-881, 2010.
7. Reyes-Gibby CC, Morrow PK, Buzdar A and Shete S: Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 10: 1146-1150, 2009.
8. Cancer Therapy Evaluation Program, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Available from: http://www.eortc.be/services/doc/ctc/CTCAE-4.03-2010-06-14-QuickReference-5x7. pdf. [Last accessed on 2011 Aug 15].
9. Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G and Reale C: Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: Results of a multicenter Italian study. Eur Neurol 61: 129-137, 2009.
10. Watson CP, Moulin D, Watt-Watson J, Gordon A and Eisenhoffer J: Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 105: 71-78, 2003.
11. Arbaiza D and Vidal O: Tramadol in the treatment of neuropathic cancer pain: A double-blind, placebo-controlled study. Clin Drug Investig 27: 75-83, 2007.
12. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH and Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 14: 65-70, 2000.
13. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ and Green MR: Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97: 2480-2486, 2003.
14. Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P and Lazzarino M: Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leuk Res 34: 471-474, 2010.
15. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E and Figg WD: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 24: 1050-1057, 2001.
16. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G and Fenton RG: Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer 110: 1042-1049, 2007.
17. Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV and Koufos C: Gabapentin monotherapy for the treatment of chemotherapyinduced neuropathic pain: A pilot study. Pain Med 9: 1209-1216, 2008.
18. Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon MH, Kim HK, Lee YW, Kim C and Lee PB: Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: A 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther 32: 2370-2385, 2010.
19. Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G and Wang H: Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 152: 514-521, 2011.
20. Gilron I, Wajsbrot D, Therrien F and Lemay J: Pregabalin for peripheral neuropathic pain: A multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 27: 185-193, 2011.
21. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A and Figg WD: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14: 4200-4205, 2008.
22. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A and Mielke S: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42: 2893-2896, 2006.